Table 1 Socio-demographic and clinical characteristics of the patients at baseline
Variable at baseline | All patients, n = 319 | Pre-UTT patients, n = 122 | UTT patients, n = 197 |
|---|---|---|---|
Age at baseline (years): median (IQR) | 7.3 (3.0–11.2) | 7.4 (3.6–11.2) | 7.2 (2.1–11.0) |
Gender | |||
Male | 164 (51.4%) | 63 (51.6%) | 101 (51.3%) |
Female | 155 (48.6%) | 59 (48.4%) | 96 (48.7%) |
Primary caregiver | |||
Both parents | 100 (31.3%) | 42 (34.5%) | 58 (29.4%) |
One parent | 175 (54.9%) | 63 (51.6%) | 112 (56.9%) |
Guardian | 44 (13.8%) | 17 (13.9%) | 27 (13.7%) |
HIV-type infection | |||
HIV-1 | 308 (96.5%) | 118 (96.7%) | 190 (96.5%) |
HIV-2 | 4 (1.3%) | 1 (0.1%) | 3 (1.5%) |
HIV-1 and HIV-2 | 7 (2.2%) | 3 (3.2%) | 4 (2.0%) |
HIV-1 RNA, log10 copies/mL: median (IQR) | 4.80 (4.07–5.49) | 4.82 (4.10–5.48) | 4.72 (3.85–5.52) |
CD4+ T-cell count | |||
Below 200 cells/µL | 58 (18.3%) | 21 (16.8%) | 37 (18.8%) |
200–349 cells/µL | 70 (21.7%) | 29 (23.4%) | 41 (20.8%) |
350–499 cells/µL | 94 (29.6%) | 34 (28.1%) | 60 (30.5%) |
500 or more cells/µL | 97 (30.4%) | 38 (31.7%) | 59 (29.9%) |
CD4+ T-cell count, cells/µL: median (IQR) | 432 (258–713) | 423 (266–741) | 466 (243–695) |
WHO clinical stage | |||
Early stage(1 and 2) | 122 (38.2%) | 45 (36.7%) | 77 (39.1%) |
Advanced stage (3 and 4) | 197 (61.8%) | 77 (63.3%) | 120 (60.9%) |
1st line ART regimen | |||
AZT/3TC/NVP | 139 (43.7%) | 54 (44.3%) | 85 (43.1%) |
AZT/3TC/EFV | 41 (12.9%) | 17 (13.7%) | 24 (12.2%) |
ABC/3TC/NVP | 58 (18.2%) | 20 (16.5%) | 38 (19.3%) |
ABC/3TC/EFV | 43 (13.3%) | 18 (14.6%) | 25 (12.7%) |
TDF/3TC/EFV | 24 (7.6%) | 10 (8.1%) | 14 (7.1%) |
ABC/3TC/LPV/r | 9 (2.8%) | 2 (1.7%) | 7 (3.6%) |
AZT/3TC/LPV/r | 5 (1.5%) | 1 (1.1%) | 4 (2.0%) |